33 search results for: disease progression
ADVENT On Air | Be on the Lookout for EoE: The Importance of Early Diagnosis
Join Dr. Aceves and Ms. Ugras as they share their insights on how to identify potential patients with EoE and the importance of early diagnosis.
Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE
Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.
ADVENT On Air | Eosinophilic Esophagitis: Steering Toward Success
Learn from Drs. Dellon and Wechsler as they discuss best practices in EoE, including highlights from EoE guidelines in the US and EU.
UEG 2025 | Understanding Type 2 Inflammation in EoE: A Case-Based Discussion
Profs. Greuter, Savarino, and Giordano discuss best practices for EoE identification, multidimensional EoE assessment, and transition of care.
ESPGHAN 2025 Pediatric EoE: Clinical Data & Long-Term Management
Dr Gutiérrez Junquera discusses ESPGHAN guidelines, clinical data, and long-term management strategies for pediatric EoE.
UEG 2025 | Bridging the Gap in EoE: Strategies for Seamless Transition of Care
Profs. Greuter, Savarino, and Giordano discuss multidimensional EoE assessment, tailoring long-term care to patient needs, and recent clinical data.
EoE Quest: Navigating the Patient Experience
Want to test your EoE knowledge while learning more about the patient journey? Try EoE Quest, an engaging and educational interactive experience.
ADVENT at San Diego, 2024
Two educational symposia at San Diego, 2024, explore the role of type 2 inflammation and the related manifestations in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.
Charting the Future: Preventing the Atopic March
In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.
